has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and tolerability of QUTENZA ® (capsaicin) 8% topical system in post-surgical neuropathic ...

The Phase III trial AV001 aims to evaluate QUTENZA ® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical ...

The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures ...

Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $4.38 per share for the third quarter of 2024, ...

Neuropathic pain affects more than 20 million people in the U.S., and at least a quarter of these cases are puzzling for ...

A recent study found that patients’ perioperative pain experience was a better predictor of chronic postsurgical pain than acute pain intensity.

Find out about the groundbreaking MDMA clinical trial for chronic nerve pain. Discover how this study aims to test the impact of MDMA compared to a placebo.

Neuropathic pain is a severe clinical condition caused by damage to the nervous system. It often feels like a burning, ...

Few autoimmune disorders are more challenging for patients than multiple sclerosis, a progressive condition that can affect ...

Event: Tear Film and Ocular Surface Society (TFOS) Conference Presentation Title: Efficacy and Safety Results of First-in-Human Phase 2 Trial of OK-101 in Dry Eye Patients Presented By: Raj Patil, ...

European researchers have mapped the most comprehensive phenotyping of neuropathic pain and identified genetic markers associated with this serious condition.

Immunophage Biomedical Co. Ltd. has divulged G-protein coupled receptor 183 (GPR183; EBI2) antagonists reported to be useful for the treatment of autoimmune disease, cancer, liver diseases, ...